Sun-Novo
688621----
Sun-Novo (688621)
Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Sun-Novo Analyst Rating
View MoreForecast & Rating
Jul 4, 2025Price forecast
¥75.0429.37%
Forecast & RatingBuy
1analysts
- Strong buy0.00%
- Buy100.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- China Finance Online · 4 hours ago
A-share volatility | JOINN's performance ignites the sector! CRO concept surges across the board, GEMPHARMATECH and ChemPartner hit 20% limit up
- Zhitong · 8 hours ago
The cell immunotherapy sector rises, HAINAN HAIYAO hits the limit up
- 科创板日报 · 8 hours ago
Traditional CRO business under pressure combined with a lack of BD revenue, Sun-Novo expects a significant loss in performance in the first half of the year
- JIN10 · 1 day ago, 05:04 AM
Sun-Novo: Expected net profit in the first half of the year to decline by 111.53% to 123.06% year-on-year
- Zhitong · Jul 3 at 07:44 AM
Sun-Novo plans to raise no more than 240 million yuan for the research and development construction project of nucleic acid drug discovery and pilot testing platform, among others
- e公司 · Jul 2 at 03:47 AM
Sun-Novo responds to annual report inquiry, analyzing the reasons and rationality behind the nearly 100% gross margin of its innovative drug-related business
